GLP-1 + GIP + Glucagon (GCG) agonist
Initially, research on pancreatic cancer revealed that blocking HGF/c-MET reduced TGF- release from cancer cells, leading to an increase in cytotoxic T-cell invasion, which culminated in the demise of cancer cells within the tumor [93]
Observed Side Effects (From Clinical Trials) In the Lancet 2021 Phase 2 trial (n=706), at the highest 4.5 mg/week dose, 88% of participants reported at least one side effect and 63% reported a GI-specific event
The breakdown of faulty red blood cells can also cause jaundice
The MHRA may consider product names, claims, imagery, testimonials, administration material, websites, social media and intended consumer use
The result is stronger angiogenesis, improved perfusion, and more efficient nutrient exchange at the tissue level